Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 2
Submit an article Journal homepage
543
Views
27
CrossRef citations to date
0
Altmetric
Original Articles

Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study

Bhavana BhatnagarDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ;The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; Correspondence[email protected]
View further author information
,
Qiuhong ZhaoDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ;The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; View further author information
,
Alice S. MimsDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ;The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; View further author information
,
Sumithira VasuDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ;The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; View further author information
,
Gregory K. BehbehaniDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ;The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; View further author information
,
Karilyn LarkinDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ;The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; View further author information
,
James S. BlachlyDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ;The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; View further author information
,
William BlumDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USAView further author information
,
Rebecca B. KlisovicDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USAView further author information
,
Amy S. RuppertDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ;The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; View further author information
,
Shelley OrwickThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; View further author information
,
Christopher OakesDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; View further author information
,
Parvathi RanganathanDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ;The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; View further author information
,
John C. ByrdDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ;The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; View further author information
,
Alison R. WalkerDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ;The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; View further author information
&
Ramiro GarzonDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ;The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; View further author information
 show all
Pages 387-396 | Received 03 Apr 2019, Accepted 01 Sep 2019, Published online: 23 Sep 2019

References

  • Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051–1062.
  • Fung HY, Chook YM. Atomic basis of CRM1-cargo recognition, release and inhibition. Seminars Cancer Biol. 2014;27:52–61.
  • Abdul Razak AR, Mau-Soerensen M, Gabrail NY, et al. First-in-class, first-in-human phase i study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34(34):4142–4150.
  • Gounder MM, Zer A, Tap WD, et al. Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol. 2016;34(26):3166–3174.
  • Kuruvilla J, Savona M, Baz R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017;129(24):3175–3183.
  • Turner JG, Dawson JL, Grant S, et al. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol. 2016;9(1):73.
  • Etchin J, Sanda T, Mansour MR, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013;161(1):117–127.
  • Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012;120(9):1765–1773.
  • Etchin J, Montero J, Berezovskaya A, et al. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia. 2016;30(1):0–9.
  • Garzon R, Savona M. A phase I clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017;129:3165.
  • Ranganathan P, Yu X, Santhanam R, et al. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood. 2015;125(17):2689–2692.
  • Simons A, Shaffer LG, Hastings RJ. Cytogenetic nomenclature: changes in the ISCN 2013 compared to the 2009 Edition. Cytogenet Genome Res. 2013;141(1):1–6.
  • Kroll KW, Eisfeld AK, Lozanski G, et al. MuCor: mutation aggregation and correlation. Bioinformatics. 2016;32(10):1557–1558.
  • Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61(19):7233–7239.
  • Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–4649.
  • Mantel N, Byar DP. Evaluation of response-time data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc. 1974;69(345):81–86.
  • Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107(16):7473–7478.
  • Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013;54(9):2003–2007.
  • Etchin J, Berezovskaya A, Conway AS, et al. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia. 2017;31(1):143–150.
  • Hing ZA, Fung HY, Ranganathan P, et al. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. Leukemia. 2016;30(12):2364–2372.
  • Cornell RF, Rossi AC, Baz R, et al. Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with refractory multiple myeloma. Blood. 2017;130(Suppl 1):3134–3134.
  • Bhatnagar B, Duong VH, Gourdin TS, et al. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Leuk Lymphoma. 2014;55(7):1533–1537.
  • Ranganathan P, Kashyap T, Yu X, et al. XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase iialpha to the nucleus. Clin Cancer Res. 2016;22(24):6142–6152.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.